On the interchangeability of biologic drug products

Statistics in Medicine

Volumn 32, Issue 3, 2013, Pages 434-441

  Endrenyi, Laszlo ^a   Chang, Chiann ^b   Chow, Shein Chung ^c   Tothfalusi, Laszlo ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Biological drugs; Biosimilarity; Interchangeability; Prescribability; Switchability

Indexed keywords

BIOLOGICAL PRODUCT; BIOSIMILAR AGENT;

ARTICLE; BIOEQUIVALENCE; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG SUBSTITUTION; FOOD AND DRUG ADMINISTRATION; LAW; MATHEMATICAL ANALYSIS; PRACTICE GUIDELINE; PRESCRIPTION; UNITED STATES;

ALGORITHMS; BIOSIMILAR PHARMACEUTICALS; CANADA; DRUG SUBSTITUTION; EUROPE; HUMANS; LEGISLATION, DRUG; UNITED STATES;

EID: 84872423673     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5569     Document Type: Article

References (31)

1. FDA. Guidance on bioavailability and bioequivalence studies for orally administrated drug products - general considerations. Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, MD, 2003. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf.
2. Health Canada. Guidance document: conduct and analysis of comparative bioavailability studies. Health Canada, Ottawa, ON, 2002. http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/prodpharma/applic-demande/guide-ld/bio/gd_cbs_ebc_ld-eng.pdf.
3. European Medicines Agency (EMA). Guideline on the investigation of bioequivalence. Committee for Medicinal Products for Human Use, London, January 20, 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf.
4. Chow S-C.Quantitative evaluation of bioequivalence/biosimilarity. Journal of Bioequivalence and Bioavailability 2011; S1. doi:10.4172/jbb.S1-002.
5. Sekhon BS.Biosimilars: an overview. Biosimilars 2011; 1:1-11.
6. FDA. Draft guidance for industry - scientific considerations in demonstrating biosimilarity to a reference product. Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research, US Food and Drug Administration, Rockville, MD, February 2012. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291128.pdf.
7. European Medicines Agency (EMEA). Guideline on similar medicinal biological products. Committee for Medicinal Products for Human Use, London, October 30, 2005. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf.
8. Health Canada. Guidance for sponsors: information and submission requirements for subsequent entry biologics (SEBs). Health Products and Food Branch, Ottawa, ON, March 5, 2010. http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/brgtherap/applic-demande/guides/seb-pbu/seb-pbu-2010-eng.pdf.
9. WHO. Guidelines on evaluation of similar biotherapeutic products (SBPs). World Health Organization, Geneva, October 19-23, 2009. http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf.
10. Nightingale SL (FDA Assoc. Commissioner). Therapeutic equivalence of generic drugs - letter to health practitioners, January 28, 1998. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm073182.htm.
11. Chow S-C, Liu J-P.Design and Analysis of Bioavailability and Bioequivalence Studies, (3rd edn). Chapman Hall/CRC Press, Taylor & Francis: New York, 2008.
12. Anderson S, Hauck WW.Consideration of individual bioequivalence. Journal of Pharmacokinetics and Biopharmaceutics 1990; 18:259-273.
13. Schall R, Luus HG.On population and individual bioequivalence. Statistics in Medicine 1993; 12:1109-1124.
14. Sheiner LB.Bioequivalence revisited. Statistics in Medicine 1992; 11:1777-1788.
15. FDA. Guidance for industry - statistical approaches to establishing bioequivalence. Center for Drug Evaluation and Research, US Food and Drug Administration:Rockville, MD, January 2001. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070244.pdf.
16. Chen M-L.Individual bioequivalence - a regulatory update (with discussion). Journal of Biopharmaceutical Statistics 1997; 7:105-111.
17. Hauck WW, Chen M-L, Hyslop T, Patnaik R, Schuirmann D, Williams RL.Mean difference vs. variability reduction: tradeoffs in aggregate measures for individual bioequivalence. International Journal of Clinical Pharmacology and Therapeutics 1996; 34:535-541.
18. Endrenyi L, Hao Y.Asymmetry of the mean-variability tradeoff raises questions about the model in investigations of individual bioequivalence. International Journal of Clinical Pharmacology and Therapeutics 1998; 36:450-457.
19. Endrenyi L, Taback N, Tothfalusi L.Properties of the estimated variance component for subject-by-formulation interaction in studies of individual bioequivalence. Statistics in Medicine 2000; 19:2867-2878.
20. Hyslop T, Hsuan F, Holder DJ.A small sample confidence interval approach to assess individual bioequivalence. Statistics in Medicine 1997; 19:2885-2897.
21. Chow S-C.Individual bioequivalence - a review of the FDA draft guidance. Drug Information Journal 1999; 33:435-444.
22. Endrenyi L, Amidon GL, Midha KK, Skelly JP.Individual bioequivalence: attractive in principle, difficult in practice. Pharmaceutical Research 1998; 15:1321-1325.
23. BPCI Act. Biologics Price Competition and Innovation Act of 2009. Federal Register. 2010; H.R. 3590-686-702. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/UCM216146.pdf.
24. FDA. Draft guidance for industry - quality considerations in demonstrating biosimilarity to a reference protein product. Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, MD, February 2012. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291134.pdf.
25. FDA. Draft guidance for industry - biosimilars: questions and answers regarding implementation of the Price Competition and Implementation Act of 2009. Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, MD, February 2012. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm273001.pdf.
26. European Medicines Agency (EMA). Concept paper on the revision of the guideline of similar biological medicinal product. Committee for Medicinal Products for Human Use, London, November 17, 2011. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/11/WC500117987.pdf.
27. European Medicines Agency (EMA). Concept paper on the revision of the guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Committee for Medicinal Products for Human Use, London, September 22, 2011. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/10/WC500115611.pdf.
28. European Medicines Agency (EMEA). Guideline on similar medicinal biological products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Committee for Medicinal Products for Human Use, London, February 22, 2006. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf.
29. Wang J, Chow S-C.On the regulatory approval pathway of biosimilar products. Pharmaceuticals 2012; 5(4):353-368.
30. Anderson S, Hauck WW.The transitivity of bioequivalence testing: potential for drift. International Journal of Clinical Pharmacology and Therapeutics 1996; 9:369-374.
31. Kay J.Chairman's Report - National Summit on Second Entry Biologics in Canada. BIOTECanada: Ottawa, ON, 2012.